Utah § 26B-4-243 Guidance for treatment with medical cannabis.

Utah Statutes

§ 26B-4-243 — Guidance for treatment with medical cannabis.

Utah § 26B-4-243

Title 26BUtah Health and Human Services Code

Ch. 26B-4Health Care - Delivery and Access

Part 26B-4-2Cannabinoid Research and Medical Cannabis

This text of Utah § 26B-4-243 (Guidance for treatment with medical cannabis.) is published on Counsel Stack Legal Research, covering Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Utah Code Ann. § 26B-4-243 (2026).

Text

The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206, shall:

(1)develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include:

(1)(a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;

(1)(b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and

(1)(c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;

(2)educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:

(2)

Free access — add to your briefcase to read the full text and ask questions with AI

The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206, shall:
(1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include:
(1)(a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;
(1)(b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and
(1)(c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;
(2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:
(2)(a) the evidence-based guidance for treatment with medical cannabis described in Subsection (1)(a);
(2)(b) relevant warnings and safety information related to medical cannabis use; and
(2)(c) other topics related to medical cannabis use as determined by the department; and
(3) develop patient product information inserts for medical cannabis products:
(3)(a) in consultation with the cannabis processing facility that created the product; and
(3)(b) that do not contain proprietary information about the product.